Current Editions
Changes to Biosecure Act create breathing room for U.S. biotechs
Impact of the bill, which targets Chinese CDMOs, on Medicare and Medicaid reimbursement is unclear
Politics, Policy & Law
How WuXi AppTec is battling the Biosecure Act
CDMO rebuts assertions in anti-China biotech bills, says it can help revitalize U.S. biomanufacturing
Politics, Policy & Law
Product Development
Epigenetic editors at ASGCT: animal models address the durability question
As the new modality advances, the promise of durability is bearing out in preclinical models
Discovery & Translation
Science spotlight: An antidote to reverse anticoagulants, two ocular gene therapies, and more
BioCentury’s roundup of translational innovations
Finance
Public equity report: iTeos, ADC Therapeutics, Eledon draw fundings
Biotechs all gave clinical updates during busy earnings week
Investments in digital, AI tech will be part of Takeda’s return-to-growth program
Pharma seeking efficiencies, agility as it looks to boost profits in 2025 and beyond
Management Tracks
Nickerson to lead Therini as CEO
Plus: Alex Gorsky joins Iconiq Capital and updates from JPMorgan and Merakris
BioCentury ISSN 1097-7201